Skip to content

Mini- Percutaneous Nephrolithotomy Versus Standard Percutaneous Nephrolithotomy in the Treatment of Renal Stones.

Mini- Percutaneous Nephrolithotomy Versus Standard Percutaneous Nephrolithotomy in the Treatment of Renal Stones. A Randomized Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04153461
Enrollment
210
Registered
2019-11-06
Start date
2019-05-01
Completion date
2021-05-01
Last updated
2019-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MINIPERC, Nephrolithiasis, NEPHROLITHOTOMY, PCNL, PNL, Stone;Renal, Urolithiasis

Keywords

urolithiasis, stone, renal, nephrolithiasis, PNL, PCNL, NEPHROLITHOTOMY, MINIPERC, MINI-PERC, BLOOD LOSS, NEPHROSTOMY SIZE

Brief summary

The EUA Urolithiasis Guidelines Panel meta-analysis suggest that mPNL is at least as efficacious and safe as sPNL for the removal of renal calculi. However, the quality of the evidence was poor, drawn mainly from small studies, the majority of which were single-arm case series, and only one of which was RCT. The risks of bias and confounding were high, highlighting the need for more reliable data from RCTs. So, the Panel recommended for more clinical research . The aim of this study is to compare between PNL and mPNL through a randomized controlled trial.

Interventions

MINIPERCUTANEOUS NEPHROLITHOTOMY USING NEPHROSCOPY 15 FR, LASER DUSTING OF THE STONE, NEPHROSTOMY TUBE 12 FIXATION

PERCUTANEOUS NEPHROLITHOTOMY USING NEPHROSCOPY 24 FR, ULTRASOUND OR LITHOCLAST DISINTEGRATION OF THE STONE AND FORCEPS EXTRACTION OF THE FRAGMENTS, NEPHROSTOMY TUBE 22 FIXATION

Sponsors

Mansoura University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patient 18 years or older. 2. ASA I or II 3. Renal stones ≥ 2 cm 4. Lower calyceal stone ≥ 1 cm 5. Failure of other modalities of treatment as ESWL and RIRS.

Exclusion criteria

1. S.creatinine \> 2mg/dl. 2. Patients with active UTI. 3. Patients on anticoagulant. 4. Age \<18 years. 5. Ureteral obstruction preventing the insertion of a ureteral stent.

Design outcomes

Primary

MeasureTime frameDescription
Assessment of stone free rate (SFR)2 yearsdefined as less than 4mm by non contrast computed tomography

Secondary

MeasureTime frameDescription
assessment of haemoglobin loss2 yearsmeasured by haemoglobin change pre and postoperative (measured by grams/ deciliter)
assessment of pain2 yearsmeasured by visual analogue scale
assessment of renal function2 yearsmeasured by serum creatinine measured by Milligram/ deciliter
assessment of patient satisfaction2 yearsmeasured by freiburg index of patient satisfaction

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026